LLY Jan 2026 630.000 call
- Yahoo Finance Video
Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market
GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies. "There's been a duopoly situation via Lilly and Novo," Richter explains. She points to Zealand (ZEAL.CO), Amgen (AMGN), and Regeneron (REGN) as companies she's watching that could become competitors in the weight-loss market. She notes that Eli Lilly and Novo Nordisk are facing limited supply as demand skyrockets. The two pharmaceutical companies have to make significant investments to expand manufacturing capabilities, and Richter explains, "I think what everybody realizes is based on the opportunity, the investment in manufacturing and supply has to come in much earlier than perhaps thought before." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
- Investor's Business Daily
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.
- Zacks
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
